Barclays
RVLP

Barclays’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Barclays’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,697
Closed -$15.6K – 5250
2023
Q1 		$15.6K Sell
13,697
-9,620
-41% -$11.5K ﹤0.01% 4696
2022
Q4 		$26.1K Buy
23,317
+20,468
+718% +$32.6K ﹤0.01% 4754
2022
Q3 		$6K Buy
+2,849
New +$5.54K ﹤0.01% 4482
2021
Q4 		– Sell
-2,425
Closed -$7K – 4864
2021
Q3 		$7K Sell
2,425
-2,684
-53% -$9.02K ﹤0.01% 4581
2021
Q2 		$15K Sell
5,109
-5,825
-53% -$17.8K ﹤0.01% 4563
2021
Q1 		$36K Buy
10,934
+6,515
+147% +$26.8K ﹤0.01% 4271
2020
Q4 		$17K Sell
4,419
-1,596
-27% -$9.2K ﹤0.01% 4699
2020
Q3 		$32K Sell
6,015
-682
-10% -$3.93K ﹤0.01% 4782
2020
Q2 		$46K Buy
6,697
+3,753
+127% +$18.4K ﹤0.01% 4965
2020
Q1 		$9K Sell
2,944
-5,282
-64% -$28.1K ﹤0.01% 5855
2019
Q4 		$57K Buy
8,226
+4,174
+103% +$22.3K ﹤0.01% 5706
2019
Q3 		$15K Sell
4,052
-4,516
-53% -$15.3K ﹤0.01% 6276
2019
Q2 		$33K Buy
8,568
+5,810
+211% +$19.3K ﹤0.01% 6270
2019
Q1 		$10K Buy
+2,758
New +$20.3K ﹤0.01% 6563

Other funds holding RVLP

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
RA
Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays's RVLP Position: Q2 2023 in Review

Barclays sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q2 2023, closing a stake of 13,697 shares — an estimated $15.6K sold.

Barclays first reported a position in RVLP in Q1 2019 and held it in 14 quarters. The position peaked at $57K in Q4 2019. 36 funds tracked by Wall St. Rank hold RVLP as of Q2 2023.

  • Barclays reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • Barclays sold 13,697 RVL Pharmaceuticals plc Ordinary Shares shares in Q2 2023, an estimated $15.6K.
  • Barclays first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q1 2019 and held it in 14 quarters.
  • Barclays's RVL Pharmaceuticals plc Ordinary Shares position peaked at $57K in Q4 2019.
  • 36 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.